Dr. Altman on Neoadjuvant Chemotherapy in High-Grade Serous Carcinoma

Alon Altman, MD
Published: Tuesday, Mar 14, 2017



Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous ovarian carcinoma.

There were a couple big studies that showed equivalence of neoadjuvant chemotherapy to primary debulking, explains Altman. Across the world, many centers have shifted to more patients receiving neoadjuvant chemotherapy followed by surgery and further chemotherapy.

However, multiple studies have shown that the outcomes for the neoadjuvant group were not as beneficial, but the reasoning is still unknown, states Altman. One of the possible explanations is the number of cycles being administered.
 


Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous ovarian carcinoma.

There were a couple big studies that showed equivalence of neoadjuvant chemotherapy to primary debulking, explains Altman. Across the world, many centers have shifted to more patients receiving neoadjuvant chemotherapy followed by surgery and further chemotherapy.

However, multiple studies have shown that the outcomes for the neoadjuvant group were not as beneficial, but the reasoning is still unknown, states Altman. One of the possible explanations is the number of cycles being administered.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x